Wrinkling of skin

CHONGQING, China, Sept. 25, 2024 /PRNewswire/ -- MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned subsidiary, Claruvis Pharmaceutical Co., has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for YY003, the world's first liquid formulation of recombinant BoNT/A, packaged in a pre-filled syringe, developed for the treatment of glabellar lines. "We are thrilled to receive FDA approval to advance the novel liquid formulation of rBoNT/A (YY003) into clinical development. This liquid-formulated recombinant BoNT/A, delivered via a prefilled device, represents a safer and more convenient option for users. The combination of a super-pure, highly effective product and its ease-of-use design offers BoNT/A users an optimized solution," said Dr. Wu Yang, Chief Scientific Officer of Claruvis, who has over 20 years of experience in botulinum toxin research and development. Claruvis Pharmaceutical, one of the few pioneering biotech companies in China, has developed the world's first recombinant BoNT/A product to reach clinical studies. The company recently completed its Phase III clinical trial for treatment of medium to severe glabellar lines and achieved all the study end points. The efficacy, safety and immunogenicity profiles demonstrated in the trial have set a remarkable milestone in the field of cosmetical use of BoNTs. On September 14th, the company has also successfully dosed the first patient in a phase II clinical trial for treatment of adult upper arm spasm in China, setting another new world record utilizing recombinant BoNT/A for the therapeutic indication. The company has started its first Biologics License Application (BLA) in China, backed by a comprehensive set of successful Phase I, II, and III clinical results. Dr. Yang added, "We believe the FDA's approval of YY003 for clinical evaluation is a significant milestone towards launching a high-quality product in the Botulinum toxin market." About MingMed MingMed Biotechnology Co., Ltd. is an innovative company dedicated to the in-house discovery and development of novel drugs that address global unmet medical needs. Our R&D team is led by global top-notch scientists and specialists. Leveraging our research and development capabilities and efficient operations, we have built an internally developed product portfolio with a diverse yet synergistic suite of four major therapeutic areas, namely recombinant botulinum toxin, ophthalmic drugs, immuno-oncology drugs and pet immune drugs. Our product pipelines include a number of first-in-class drug candidates, and the major products have moved forward to commercialization. About Claruvis Pharmaceutical Claruvis, a non-wholly owned subsidiary of MingMed Biotechnology, is strategically focus on the development, production and commercialization of botulinum toxin products utilizing recombinant protein technology. The R&D team is formed by top-notch global scientists and senior American Chinese scholars with in-depth knowledge and experience in botulinum toxin products. Marking a significant milestone, Claruvis has pioneered the development of the world's first recombinant type A BoNT product on a self-developed R&D platform. Excellent operational capability supported by a globally competitive R&D platform will continue to drive Claruvis' innovation and fast development in the rBoNT area to address the vast number of unmet aesthetic and therapeutic medical needs worldwide. Contact: [email protected] SOURCE MingMed Biotechnology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

PARK CITY, Utah, July 11, 2023 /PRNewswire/ -- Sentient ® , LLC, the leading full-service provider to the aesthetic care industry, is proud to announce that Tixel—its non-invasive skin resurfacing technology—has received the prestigious 2023 NewBeauty Award for 'Best Resurfacing Treatment for Wrinkles.' The state-of-the-art treatment was recognized by NewBeauty magazine because "dermatologists and patients alike are loving the results of Tixel, which delivers short bursts of thermal energy into the outer layers of skin without damaging the deeper layers to boost collagen for a smoother look." Continue Reading Sentient's Tixel Receives NewBeauty Award for 'Best Resurfacing Treatment for Wrinkles' Tweet this The NewBeauty Awards showcase top products and treatments across a variety of categories ranging from innovative in-office procedures to best skin-care selections. More than 10,000 submissions were vigorously tested and vetted by NewBeauty editors and industry experts throughout the year. Sentient's Tixel device uses the first and only thermal-mechanical action technology to resurface skin. Tixel's titanium heated tip contains 81 tiny pyramid-shaped pins which heat up to 400 degrees Celsius. When briefly touched to the skin, the thermal energy is transferred directly to its top layers, creating micro damage that stimulates collagen production improving skin quality and reducing lines, wrinkles, stretch marks, enlarged pores, age spots and more. This unique nonsurgical treatment can provide noticeable results not only on the face, but also the neck, chest, and the backs of hands. Makeup can be applied the day after treatment, and pain and social downtime are minimal compared to laser and radio frequency treatments. "Sentient is thrilled to receive this recognition," said Chris Cella, Chief Executive Officer of Sentient. "We look forward to continuing to provide cutting-edge solutions for skin care." Proven on a global scale, Tixel has been used in Europe since 2011 and was cleared by the FDA for treatment of all skin types two years ago. By making Tixel's cutting-edge technology available in the U.S. – along with world class service to support it – Sentient is helping to drastically improve practices' abilities to address patients' evolving treatment preferences by developing collaborative relationships that meet clients' equipment maintenance, support and device technology needs. ABOUT SENTIENT Sentient ™ is the aesthetic medical device industry's leading full-service provider, offering advanced technology and industry-leading service and financing, delivered with integrity and transparency. Sentient takes pride in its transformational business practices as it sells, designs, repairs, fine-tunes, and implements the complex devices that help sculpt bodies, treat skin, and improve silhouettes. Sentient is committed to affordability and offers flexible financing, device maintenance, and a superior certification and warranty program to assure future performance. Sentient is the premier company in the U.S. offering an exceptional suite of advanced proprietary technologies to meet the expanding needs of practices of all sizes, from its Park City, Utah, location to nationwide. With hundreds of longstanding professional relationships and more than ten years heritage providing the best in refurbished equipment, Sentient's industry-leading service model provides quality laser and medical device repair and refurbishment services for 84 types of medical and cosmetic systems, to the FDA standards required of each manufacturer. Sentient is dedicated to building a collaborative relationship with its clients to help significantly enhance their practice efficiency, drive stronger profitability, and, most importantly, deliver an exceptional client experience. For more information visit . Media Contact: Ivy Cohen Ivy Cohen Corporate Communications (212) 399-0026 [email protected] SOURCE Sentient

WASHINGTON, June 27, 2023 /PRNewswire/ -- The nonprofit International Window Film Association (IWFA) is using the Centers For Disease Control and Prevention's UV Safety Month to warn consumers that some of the sun's harmful ultraviolet (UV) radiation can pass directly through unprotected glass in buildings and vehicles and damage skin and eyes. The sun emits radiation in the form of Ultraviolet or UV energy, which is classified into three types: UV-A, UV-B and UV-C. The earth's ozone layer blocks the most damaging UV-C light, but UV-B (which causes sunburns) and UV-A (which can penetrate deep into the skin and eyes) rays reach the earth's surface. "Just because you are sitting behind a glass window, even if it has darkly colored glass, you are not fully protected from UV-A radiation, unless the glass has been treated with UV blockers, which window films contain and they can stop 99 percent of the sun's UV-A rays," said Darrell Smith, executive director of the IWFA. Over time, the exposure to UV-A accumulates and may lead to skin cancers, including melanoma, basal cell, and squamous cell cancers. Frequent unprotected sunlight exposure may cause leathery skin, liver spots, wrinkles, cataracts, cornea damage and even vision loss. While darker skin pigmentation may lower the risk of developing skin cancer, research shows that people of color die from melanoma at a higher rate than white people. Legendary reggae star Bob Marley died at age 36 from a malignant melanoma that started under a toe nail. Window films may be installed on a vehicle's rear and side windows, as allowed by local regulation, and also on a building's windows for year-round UV protection. There are other benefits too, such as energy savings, fade reduction, safety and glare reduction. To help consumers learn more, the IWFA has a local window film dealer and installer locator on its website. About The International Window Film Association The International Window Film Association (IWFA) () is a nonprofit industry body of window film dealers, distributors, and manufacturers that facilitates the growth of the window film industry through education, research, advocacy and public awareness. When you look for window film, look for the IWFA logo. Like us on Facebook, follow us on LinkedIn and see more information on YouTube. SOURCE International Window Film Association